- Home
- FCT vs CLLS Comparison
FCT vs CLLS Comparison
Compare FCT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCT
- CLLS
- Stock Information
- Founded
- FCT 2004
- CLLS 1999
- Country
- FCT United States
- CLLS France
- Employees
- FCT N/A
- CLLS N/A
- Industry
- FCT Finance Companies
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- FCT Finance
- CLLS Health Care
- Exchange
- FCT Nasdaq
- CLLS Nasdaq
- Market Cap
- FCT 261.0M
- CLLS 260.8M
- IPO Year
- FCT N/A
- CLLS 2007
- Fundamental
- Price
- FCT $10.07
- CLLS $2.85
- Analyst Decision
- FCT
- CLLS Buy
- Analyst Count
- FCT 0
- CLLS 1
- Target Price
- FCT N/A
- CLLS $4.00
- AVG Volume (30 Days)
- FCT 106.8K
- CLLS 286.8K
- Earning Date
- FCT 01-01-0001
- CLLS 08-04-2025
- Dividend Yield
- FCT 11.29%
- CLLS N/A
- EPS Growth
- FCT N/A
- CLLS N/A
- EPS
- FCT N/A
- CLLS N/A
- Revenue
- FCT N/A
- CLLS $63,438,000.00
- Revenue This Year
- FCT N/A
- CLLS N/A
- Revenue Next Year
- FCT N/A
- CLLS $4.90
- P/E Ratio
- FCT N/A
- CLLS N/A
- Revenue Growth
- FCT N/A
- CLLS 223.09
- 52 Week Low
- FCT $9.45
- CLLS $1.10
- 52 Week High
- FCT $10.42
- CLLS $3.24
- Technical
- Relative Strength Index (RSI)
- FCT 47.00
- CLLS 62.05
- Support Level
- FCT $9.99
- CLLS $2.70
- Resistance Level
- FCT $10.09
- CLLS $2.81
- Average True Range (ATR)
- FCT 0.08
- CLLS 0.27
- MACD
- FCT -0.02
- CLLS -0.01
- Stochastic Oscillator
- FCT 27.42
- CLLS 51.85
About FCT First Trust Senior Floating Rate Income Fund II of Beneficial Interest
First Trust Senior Floating Rate Income Fund II is a United States-based diversified, closed-end management investment company. Its investment objective is to seek a high level of current income. As a secondary objective, it attempts to preserve capital. The fund invests in a portfolio of senior secured floating-rate corporate loans (Senior Loans) of companies from different industries, such as Insurance, Software, Health Care Providers and Services, Professional Services, Health Care Technology, IT Services, and others.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.